

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023147 A1

(51) International Patent Classification:

G01N 33/573 (2006.01) A61P 35/00 (2006.01)
A61K 31/198 (2006.01) G01N 33/53 (2006.01)

(21) International Application Number:

PCT/US2022/040588

(22) International Filing Date:

17 August 2022 (17.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/234,507 18 August 2021 (18.08.2021) US
63/234,517 18 August 2021 (18.08.2021) US
63/280,792 18 November 2021 (18.11.2021) US

(71) Applicant: **FAETH THERAPEUTICS, INC.** [US/US];
237 Kearny Street #9245, San Francisco, California 94108
(US).

(72) Inventors: **MADDOCKS, Oliver D.K.**; c/o Faeth Therapeutics, Inc., 237 Kearny Street #9245, San Francisco, California 94108 (US). **TYRAKIS, Petros**; c/o Faeth Therapeutics, Inc., 237 Kearny Street #9245, San Francisco, California 94108 (US). **YOUNG, Todd**; c/o Faeth Therapeutics, Inc., 237 Kearny Street #9245, San Francisco, California 94108 (US).

tics, Inc., 237 Kearny Street #9245, San Francisco, California 94108 (US).

(74) Agent: **CHOW, Carmen**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PERSONALIZED MODULATION THERAPY FOR CANCER




FIG. 8

(57) Abstract: Disclosed herein are methods and compositions to predict a response of a subject to a nutrient modulation therapy. Restricting the uptake of at least one amino acid by cancer cells can be used to treat or delay cancer. In some embodiments, the nutrition modulation therapy is a dietary product that is substantially devoid of at least one amino acid.

WO 2023/023147 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*